Search results for "plasminogen activator inhibitor-1"

showing 10 items of 23 documents

Plasminogen activator inhibitor‐1 augments damage by impairing fibrinolysis after traumatic brain injury

2019

Objective Plasminogen activator inhibitor-1 (PAI-1) is the key endogenous inhibitor of fibrinolysis, and enhances clot formation after injury. In traumatic brain injury, dysregulation of fibrinolysis may lead to sustained microthrombosis and accelerated lesion expansion. In the present study, we hypothesized that PAI-1 mediates post-traumatic malfunction of coagulation, with inhibition or genetic depletion of PAI-1 attenuating clot formation and lesion expansion after brain trauma. Methods We evaluated PAI-1 as a possible new target in a mouse controlled cortical impact (CCI) model of traumatic brain injury. We performed the pharmacological inhibition of PAI-1 with PAI-039 and stimulation b…

Male0301 basic medicineTraumatic brain injurymedicine.medical_treatmentBrain damagePharmacologyLesionMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBrain Injuries TraumaticSerpin E2FibrinolysisAnimalsMedicineThrombusResearch ArticlesIndoleacetic Acidsbusiness.industryFibrinolysisBrainmedicine.diseaseMice Inbred C57BL030104 developmental biologyNeurologychemistryPlasminogen activator inhibitor-1Neurology (clinical)medicine.symptombusinessPlasminogen activator030217 neurology & neurosurgeryIntravital microscopyResearch ArticleAnnals of Neurology
researchProduct

Plaque and blood vulnerability in ST segment elevation myocardial infarction patients: association between lesion morphology using intravascular ultr…

2013

AIM The purpose of the study was to evaluate associations between iMap intravascular ultrasound tissue characterization of culprit and nonculprit lesions in infarct-related artery and plasma biomarkers during ST segment elevation myocardial infarction (STEMI) and at 10-month follow-up. METHODS AND RESULTS Sixty-three STEMI patients at the time of index hospitalization and 10-month follow-up underwent coronary angiography and intravascular ultrasound with iMap tissue characterization of the culprit artery. Proximal and culprit segments were analyzed. A higher percentage of necrotic tissue in the nonculprit segment was found in patients in the top soluble intercellular adhesion molecule 1 (sI…

MaleAcute coronary syndromemedicine.medical_specialtyTime FactorsMyocardial InfarctionCoronary AngiographyCulpritLesionchemistry.chemical_compoundNecrosisPercutaneous Coronary InterventionPredictive Value of TestsInternal medicineIntravascular ultrasoundPlasminogen Activator Inhibitor 1medicineST segmentHumansMyocardial infarctionProspective StudiesUltrasonography InterventionalAgedmedicine.diagnostic_testbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseIntercellular Adhesion Molecule-1Coronary VesselsFibrosisPlaque Atheroscleroticmedicine.anatomical_structureTreatment OutcomechemistryPlasminogen activator inhibitor-1CardiologyFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersArteryCoronary artery disease
researchProduct

SARS CoV2 infection _The longevity study perspectives

2021

Graphical abstract

MaleAgingssRNA single-stranded RNARFLP restriction fragment length polymorphismHSPs heat shock proteinsReviewPTMs post-translational modificationsSevere Acute Respiratory SyndromeBiochemistryHIV-1 human immunodeficiency virus-1TNF-α tumor necrosis factor-αEC endothelial cells0302 clinical medicineFluAV influenza A virusI insertionMedicineIFN-γ interferon-γDIC disseminated intravascular coagulationPCR Polymerase Chain Reactionmedia_commonAged 80 and overLongevityRBD receptor-binding domainNeurologyLongevity modelMI myocardial infarctionNK natural killerhPIV2 human parainfluenza virus type 2media_common.quotation_subjectResearching genetic basis of resistance and potential pharmacological targetsLongevityDBP diastolic blood pressureNF-Kb nuclear transcription factor kBRANTES regulated upon activation normal T cell expressed and secretedMphi human macrophages03 medical and health sciencesCox 2 cyclooxygenase 2ORF open reading framePT prothrombin timeSettore MED/05 - Patologia ClinicaHumansMolecular BiologyInflammatory genesARDS acute respiratory distress syndromeNO nitric oxideD deletionCpGIs CpG islandsT2DM type 2 diabetes mellitusmedicine.diseaseFDP fibrin degradation products030104 developmental biologySARS CoV2 severe acute respiratory syndrome Coronavirus 2 virusImmunologyBMI body max indexItalian nonagenarians/centenariansRSV respiratory syncytial virusComplication030217 neurology & neurosurgeryMAPK mitogen-activated protein kinaseIP-10 IFN-γ -Inducible Protein 1040301 basic medicineAT1R activity of angiotensin 1 receptorsDCs dentritic cellsSSCP single strand conformation polymorphismACE/DD polymorphism of the angiotensin converting enzymeFGF21 fibroblast growth factor 21TLR4 toll-like receptor 4NAD nicotinamide adenine dinucleotideACE angiotensin-I converting enzymeAT2R activity of angiotensin 2 receptorsCOVID-19 Coronavirus disease 2019Respiratory distressACE2 angiotensin converting enzyme 2MKP-1 mitogen-activated protein kinase phosphatase-1 ()PD protease domainSNP single nucleotide polymorphismEH essential hypertensionTNFR tumor necrosis factor receptorINR international normalized ratio of the prothrombin timePAI-1 plasminogen activator inhibitor-1Ang angiotensinLPS lipopolysaccharideMCP1 monocyte chemoattractant protein-1medicine.symptomaPTT partial thromboplastin timeBiotechnologyDUSP1 dual specificity phosphatase 1Coronavirus disease 2019 (COVID-19)PC prostate cancerRAS renin-angiotensin aldosterone systemCCR5Δ32 genetic variant of chemokine receptorCOVID-19 Researching genetic basis of resistance and potential pharmacological targets Italian nonagenarians/centenarians Longevity modelAsymptomaticSARS-1 severe acute respiratory syndrome virus 1SIRT-1 Sirtuin 1Th1 t-helper lymphocyte type 1Immune systemROS reactive oxygen speciesTGF-β transforming growth factor betaET-1 endothelin-1ComputingMethodologies_COMPUTERGRAPHICSADAM-17 metallopeptidase domain 17business.industrySARS-CoV-2SBP systolic blood pressureCOVID-19HDACs histone deacetylasesComorbidityImmune Systembusiness5-LO lipoxygenase 5Ageing Research Reviews
researchProduct

2-Methoxyestradiol confers neuroprotection and inhibits a maladaptive HIF-1α response after traumatic brain injury in mice

2014

HIF-1α is pivotal for cellular homeostasis in response to cerebral ischemia. Pharmacological inhibition of HIF-1α may reduce secondary brain damage by targeting post-translational mechanisms associated with its proteasomal degradation and nuclear translocation. This study examined the neuroprotective effects of 2-methoxyestradiol (2ME2), the involved HIF-1α-dependent response, and alternative splicing in exon 14 of HIF-1α (HIF-1α∆Ex14) after traumatic brain injury (TBI) in mice. Intraperitoneal 2ME2 administration 30 min after TBI caused a dose-dependent reduction in secondary brain damage after 24 h. 2ME2 was physiologically tolerated, showed no effects on immune cell brain migration, and …

MaleTraumatic brain injuryBlotting WesternIschemiaCellular homeostasisBrain damagePharmacologyBiologyBiochemistryNeuroprotectionBrain IschemiaMitochondrial ProteinsMiceCellular and Molecular Neurosciencechemistry.chemical_compoundPlasminogen Activator Inhibitor 1medicineAnimalsCell NucleusNeuronsEstradiolTumor Necrosis Factor-alphaAlternative splicingMembrane ProteinsExonsHypoxia-Inducible Factor 1 alpha Subunitmedicine.diseaseImmunohistochemistryUp-RegulationMice Inbred C57BLAlternative SplicingProtein TransportNeuroprotective AgentsGene Expression RegulationchemistryBrain InjuriesPlasminogen activator inhibitor-1Tumor necrosis factor alphamedicine.symptomNeuroscienceInjections IntraperitonealSubcellular FractionsJournal of Neurochemistry
researchProduct

Immunoinflammatory activation during the acute phase of lacunar and non-lacunar ischemic stroke: Association with time of onset and diabetic state

2006

Several studies have stressed the involvement of inflammation in the pathophysiology of acute brain ischemia, but the role of immunoinflammatory activation in diabetic stroke patients has not yet been fully evaluated. The aim of our study was to evaluate immunoinflammatory activation of acute phase of stroke in relation to time of symptoms onset, diabetic state and diagnostic subtype. We enrolled 60 patients (32 diabetics; 28 non- diabetics) with acute ischemic stroke and 123 subjects without acute ischemic stroke, and measured levels of IL-1β, TNF-α, IL-6, IL-10, E-selectin, P-selectin, sICAM-1, sVCAM-1, VWF, 24–72 h and 7–10 days after stroke onset; TPA, PAI-1 plasma levels at 24–72h. Ou…

Malemedicine.medical_specialtyTime FactorsImmunologyInflammationDiseaseBrain IschemiaBrain ischemia03 medical and health scienceschemistry.chemical_compound0302 clinical medicinestroke diabetes mellitusInternal medicineDiabetes mellitusPlasminogen Activator Inhibitor 1medicineDiabetes MellitusImmunology and AllergyHumanscardiovascular diseasesStrokeAgedPharmacologyAged 80 and overInflammationbusiness.industryTumor Necrosis Factor-alphaMiddle Agedmedicine.diseaseIntercellular Adhesion Molecule-1PathophysiologyStrokechemistry030220 oncology & carcinogenesisPlasminogen activator inhibitor-1Acute DiseaseCardiologyFemalemedicine.symptombusinessSelectin030215 immunologyInterleukin-1
researchProduct

Circulating adhesion molecules, matrix metalloproteinase-9, plasminogen activator inhibitor-1, and myeloperoxidase in coronary artery disease patient…

2010

There are many pathophysiological mechanisms underlying reciprocal relationships between changes in cytokines and insulin resistance in metabolic and cardiovascular disorders. The aim of this study was to evaluate alterations in soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble E-selectin (sE-selectin), matrix metalloproteinase-9 (MMP-9), plasminogen activator inhibitor-1 (PAI-1), and myeloperoxidase (MPO) levels, and their relation to insulin resistance in coronary artery disease (CAD) patients with stable and unstable angina (SAP, UAP).Non-diabetic CAD patients were classified into two groups: 22 patients with SAP and 22 pati…

Malemedicine.medical_specialtymedicine.medical_treatmentClinical BiochemistryCoronary Artery DiseaseBiochemistryAngina PectorisCoronary artery diseasechemistry.chemical_compoundInsulin resistanceInternal medicinePlasminogen Activator Inhibitor 1medicineHumansAgedPeroxidasebiologyCell adhesion moleculeUnstable anginabusiness.industryBiochemistry (medical)General MedicineMiddle Agedmedicine.diseaseEndocrinologyCytokineMatrix Metalloproteinase 9chemistryCase-Control StudiesMyeloperoxidasePlasminogen activator inhibitor-1biology.proteinFemaleInsulin ResistancebusinessCell Adhesion MoleculesPlasminogen activatorClinica Chimica Acta
researchProduct

The association between the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor-1 gene and extension of postsurgical calf vein …

2013

The objective of this study was to evaluate whether the presence of a plasminogen activator inhibitor type 1 (PAI-1) promoter polymorphism 4G/5G could significantly influence the proximal extension of vein thrombosis in spite of anticoagulant treatment in patients with calf vein thrombosis (CVT) following orthopaedic, urological and abdominal surgery. We studied 168 patients with CVT, who had undergone orthopaedic, urological and abdominal surgery, subdivided as follows: first, 50 patients with thrombosis progression; second, 118 patients without thrombosis progression. The 4G/5G polymorphism of the plasminogen activator inhibitor 1 was evaluated in all patients and in 70 healthy matched co…

Malemedicine.medical_specialtymedicine.medical_treatmentGastroenterologychemistry.chemical_compoundPostoperative ComplicationsGene FrequencyRisk FactorsInternal medicineFibrinolysisPlasminogen Activator Inhibitor 1Factor V LeidenmedicineOdds RatioHumansGenetic Predisposition to Disease4G/5G genotype PAI-1 thrombotic lesionsPromoter Regions GeneticAllelesAgedVenous ThrombosisPolymorphism Geneticbusiness.industryHematologyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseNadroparin calciumThrombosisSurgerychemistryPlasminogen activator inhibitor-1Case-Control StudiesFemalebusinessPlasminogen activatorAbdominal surgerymedicine.drugBlood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct

Residual vein thrombosis and onset of post-thrombotic syndrome: Influence of the 4G/5G polymorphism of plasminogen activator inhibitor-1 gene

2013

Abstract Background Plasminogen activator inhibitor-1 (PAI-1) is the most important inhibitor of plasminogen activator. The functional 4G/5G polymorphism of the gene coding for PAI-1 may affect PAI-1 plasmatic activity, influencing the imbalance between coagulation and fibrinolysis cascades. In this prospective cohort analytic study, we investigated the role of this single nucleotide polymorphism in the persistence of thrombotic lesion and the occurrence of post-thrombotic syndrome. Patients/Methods In a group of 168 patients with post-surgical deep vein thrombosis of the legs, we analyzed the 4G/5G polymorphism in the promoter of PAI-1 gene and plasmatic PAI-1 activity. Enrolled patients w…

Malemedicine.medical_specialtypost-thrombotic syndrome plasminogen activator inhibitor-1 geneDeep veinmedicine.medical_treatmentSingle-nucleotide polymorphismPolymorphism Single NucleotideGastroenterologyPostthrombotic SyndromeCohort Studieschemistry.chemical_compoundInternal medicinePlasminogen Activator Inhibitor 1FibrinolysismedicineHumansGenetic Predisposition to DiseaseProspective StudiesAllelesVenous ThrombosisPolymorphism Geneticbusiness.industryHematologyHeparinMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareThrombosismedicine.anatomical_structurechemistryPlasminogen activator inhibitor-1ImmunologyFemalebusinessPlasminogen activatormedicine.drugPost-thrombotic syndromeThrombosis Research
researchProduct

Node-Negative Breast Cancer: Which Patients Should Be Treated?

2010

Adjuvant systemic therapy has led to markedly improved outcome in early-stage breast cancer. However, the absolute gains from chemotherapy might be modest in node-negative patients. Adjuvant chemotherapy is the only option for triple-negative breast cancer patients and should be used with trastuzumab in HER2-positive patients. Considering the large group of patients with some degree of endocrine responsiveness, adding chemotherapy according to risk is an option. At present, we guide our therapeutic decisions using clinicopathologic risk classifications like the St. Gallen risk category or Adjuvant! online. A downside of these risk estimations is a low specificity and consequently the risk f…

Oncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentReview Articlemedicine.diseaseSystemic therapySurgeryClinical trialchemistry.chemical_compoundBreast cancerOncologychemistryTrastuzumabInternal medicinePlasminogen activator inhibitor-1medicineSurgerybusinessPlasminogen activatorAdjuvantmedicine.drugBreast care (Basel, Switzerland)
researchProduct

Variations of components of the plasminogen activation system with the cell cycle in benign prostate tissue and prostate cancer

2001

Background: Components of the fibrinolytic system are involved in tumor cell invasion and metastasis. Previous investigations suggested a cell cycle-dependent expression of urokinase-type plasminogen activator (u-PA) in epithelial cells. In order to determine a correlation of cell cycle phases with the fibrinolytic system, we investigated the expression of u-PA, tissue-type plasminogen activator (t-PA), and plasminogen activator inhibitor type 1 (PAI-1) in normal and tumor-containing prostate extracts and analyzed a possible relationship with flow cytometry-determined proliferative activity of the samples. Cell cycle phases were correlated with fibrinolytic parameters in prostate tissue. Me…

PCA3medicine.medical_specialtyProliferation indexBiophysicsCell BiologyHematologyBiologyCell cyclemedicine.diseasePathology and Forensic MedicineMetastasischemistry.chemical_compoundProstate cancerEndocrinologymedicine.anatomical_structureEndocrinologychemistryProstatePlasminogen activator inhibitor-1Internal medicinemedicineCancer researchPlasminogen activatorCytometry
researchProduct